DK2131860T3 - Anti-sclerostin-antistoffer - Google Patents

Anti-sclerostin-antistoffer

Info

Publication number
DK2131860T3
DK2131860T3 DK08731905.9T DK08731905T DK2131860T3 DK 2131860 T3 DK2131860 T3 DK 2131860T3 DK 08731905 T DK08731905 T DK 08731905T DK 2131860 T3 DK2131860 T3 DK 2131860T3
Authority
DK
Denmark
Prior art keywords
sclerostin antibodies
sclerostin
antibodies
Prior art date
Application number
DK08731905.9T
Other languages
English (en)
Inventor
Andrew Ihor Korytko
David Matthew Marquis
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2131860T3 publication Critical patent/DK2131860T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK08731905.9T 2007-03-20 2008-03-11 Anti-sclerostin-antistoffer DK2131860T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (en) 2007-03-20 2008-03-11 Anti-sclerostin antibodies

Publications (1)

Publication Number Publication Date
DK2131860T3 true DK2131860T3 (da) 2014-01-13

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08731905.9T DK2131860T3 (da) 2007-03-20 2008-03-11 Anti-sclerostin-antistoffer

Country Status (32)

Country Link
US (3) US7744874B2 (da)
EP (2) EP2131860B1 (da)
JP (2) JP2010524846A (da)
KR (1) KR101123487B1 (da)
CN (1) CN101646457B (da)
AU (1) AU2008229141B2 (da)
BR (1) BRPI0809026A2 (da)
CA (1) CA2682212C (da)
CO (1) CO6230999A2 (da)
CR (1) CR11004A (da)
CY (1) CY1114784T1 (da)
DK (1) DK2131860T3 (da)
DO (1) DOP2009000223A (da)
EA (1) EA018204B1 (da)
EC (1) ECSP099658A (da)
ES (1) ES2446293T3 (da)
HK (1) HK1138790A1 (da)
HR (1) HRP20140108T1 (da)
IL (1) IL200437A0 (da)
MA (1) MA31308B1 (da)
MX (1) MX2009010051A (da)
MY (1) MY149129A (da)
NZ (1) NZ578870A (da)
PL (1) PL2131860T3 (da)
PT (1) PT2131860E (da)
RS (1) RS53157B (da)
SI (1) SI2131860T1 (da)
SV (1) SV2009003374A (da)
TN (1) TN2009000383A1 (da)
UA (1) UA96474C2 (da)
WO (1) WO2008115732A2 (da)
ZA (1) ZA200906345B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568033A (en) 1998-11-27 2011-04-29 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
CN101646457B (zh) * 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
UA107490C2 (uk) 2010-04-07 2015-01-12 Еббві Інк. TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
CA2795886A1 (en) 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
PT3195880T (pt) 2010-05-14 2020-02-21 Amgen Inc Formulações de anticorpos antiesclerostina de concentração elevada
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
CN103189074A (zh) 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
HUE053720T2 (hu) 2011-01-14 2021-07-28 Univ California ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
CA2828000A1 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
EP2699261B1 (en) 2011-04-19 2018-07-11 Amgen Inc. Method for treating osteoporosis
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
ES2667554T3 (es) * 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
CA2853357A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
CA2853258A1 (en) * 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
JP6121432B2 (ja) 2011-10-24 2017-04-26 アッヴィ・インコーポレイテッド Ｔｎｆおよびｉｌ−１７に対する双特異性免疫結合剤
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MX2017008819A (es) 2014-12-30 2018-03-14 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
HUE052528T2 (hu) * 2015-03-13 2021-05-28 Jiangsu Hengrui Medicine Co Anti szklerosztin antitest, antigénkötõ fragmens és annak orvosi használata
IL261200B2 (en) 2016-03-01 2023-03-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
EP3532501A1 (en) * 2016-10-28 2019-09-04 Eli Lilly and Company Anti-rankl antibodies and uses thereof
WO2018085468A1 (en) * 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3868780A1 (en) * 2016-12-21 2021-08-25 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
WO2018139623A1 (en) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
WO2019020069A1 (zh) * 2017-07-27 2019-01-31 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
JP7425041B2 (ja) 2018-08-10 2024-01-30 アムジエン・インコーポレーテツド 抗体医薬製剤を作製する方法
AU2020212534A1 (en) * 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2022544495A (ja) 2019-08-12 2022-10-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体製剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568033A (en) 1998-11-27 2011-04-29 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
WO2004047609A2 (en) * 2002-11-27 2004-06-10 Visiopharm Aps A method and a system for establishing a quantity measure for joint destruction
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2006046935A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
CN101646457B (zh) * 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体

Also Published As

Publication number Publication date
BRPI0809026A2 (pt) 2014-09-23
US20100221263A1 (en) 2010-09-02
NZ578870A (en) 2012-01-12
CR11004A (es) 2009-11-02
ZA200906345B (en) 2010-11-24
PL2131860T3 (pl) 2014-05-30
MA31308B1 (fr) 2010-04-01
RS53157B (en) 2014-06-30
WO2008115732A2 (en) 2008-09-25
EA018204B1 (ru) 2013-06-28
ES2446293T3 (es) 2014-03-07
EP2664346A1 (en) 2013-11-20
US7988970B2 (en) 2011-08-02
SI2131860T1 (sl) 2014-02-28
JP2013151504A (ja) 2013-08-08
CN101646457A (zh) 2010-02-10
CO6230999A2 (es) 2010-12-20
DOP2009000223A (es) 2009-10-15
WO2008115732A3 (en) 2008-12-11
US8257704B2 (en) 2012-09-04
HK1138790A1 (en) 2010-09-03
AU2008229141B2 (en) 2013-02-07
CA2682212A1 (en) 2008-09-25
MX2009010051A (es) 2009-10-12
JP2010524846A (ja) 2010-07-22
MY149129A (en) 2013-07-15
ECSP099658A (es) 2009-10-30
US7744874B2 (en) 2010-06-29
CN101646457B (zh) 2013-05-01
SV2009003374A (es) 2011-01-10
IL200437A0 (en) 2010-04-29
CY1114784T1 (el) 2016-12-14
JP5758933B2 (ja) 2015-08-05
US20110250205A1 (en) 2011-10-13
KR101123487B1 (ko) 2012-03-23
TN2009000383A1 (en) 2010-12-31
EP2131860B1 (en) 2013-12-18
HRP20140108T1 (hr) 2014-02-28
EA200970874A1 (ru) 2010-02-26
EP2131860A2 (en) 2009-12-16
KR20090114462A (ko) 2009-11-03
AU2008229141A1 (en) 2008-09-25
PT2131860E (pt) 2014-03-04
CA2682212C (en) 2014-05-06
UA96474C2 (en) 2011-11-10
US20090060924A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0907237A2 (pt) Anticorpo anti-cldn6
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
DK2066695T3 (da) Anti-myostatin-antistoffer
SMT201700083B (it) Anticorpi monoclonali
NO344963B1 (no) Humanisert antistoff
BRPI0922800A2 (pt) anticorpos c-met
BRPI0809677A2 (pt) Anticorpos anti-ige
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
DK2234600T3 (da) Antistofformulering
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0814003A2 (pt) Formulações de anticorpo
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0820298A2 (pt) anticorpos anti-vegf composições e métodos
DK2059533T3 (da) Multispecifikke antistoffer
BRPI0820073A2 (pt) Anticorpos anti-axl
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.